Aptahem AB logo

APTA TO 5 - Aptahem AB News Story

SEK0.1 0.1  185.7%

Last Trade - 13/04/21

Sector
Healthcare
Size
Micro Cap
Market Cap £8.52m
Enterprise Value £6.09m
Revenue £n/a
Position in Universe 1615th / 1830

BRIEF-Aptahem: Strengthened Results With Apta-1 From Completed NHP Study

Fri 11th October, 2019 12:51pm
Oct 11 (Reuters) - Aptahem AB  APTA.TE :
    * APTAHEM ANNOUNCES STRENGTHENED RESEARCH RESULTS WITH
APTA-1 FROM
COMPLETED NHP STUDY
    * NEW PRECLINICAL RESULTS CONTINUE TO SUPPORT APTA-1'S
MULTIFUNCTIONAL DRUG CANDIDATE POTENTIAL WITHIN TREATMENT OF
SEPSIS
    * NHP STUDY HAS SHOWN THAT APTA-1 HAS ABILITY TO BOTH
DIRECTLY AND
INDIRECTLY AFFECT MECHANISMS THAT LEAD TO A POSITIVE CHANGE IN
HEALTH FOR APTA-1-TREATED ANIMALS THROUGH NOW FURTHER CLARIFIED
MECHANISMS OF ACTION
    * AN ADDITIONAL DISCOVERY FROM NHP STUDY IS APTA-1'S ABILITY
TO
STIMULATE INCREASED PRODUCTION OF PROTEIN THAT HELPS BODY TO
CLEAR DAMAGED OR DEAD CELLS (APOPTOSIS)
    * ADDITIONAL DISCOVERY INDICATES PRELIMINARY THAT APTA-1 MAY
PLAY
AN IMPORTANT ROLE AS PROTECTION AGAINST AUTOIMMUNE DISEASES
    * COMPANY WILL IN COMING FUTURE INVESTIGATE ADDITIONAL
PATENT
OPPORTUNITIES BASED ON THESE NEW RESEARCH RESULTS

Source text for Eikon:  ID:nWkr6X6Zgp 
Further company coverage:  APTA.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.